Stay updated with breaking news from Nasdaq mrns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month […] ....
Opaleye Management Inc. bought a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 826,200 shares of the biopharmaceutical company’s stock, valued at approximately $3,288,000. Marinus Pharmaceuticals makes up approximately 1.1% of […] ....
StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on MRNS. Royal Bank of Canada reduced their price objective on Marinus Pharmaceuticals from $23.00 to $22.00 […] ....
StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. MRNS has been the subject of a number of other reports. SVB Leerink reduced their price objective on shares of Marinus Pharmaceuticals from […] ....
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price target lowered by Truist Financial from $50.00 to $42.00 in a report issued on Friday, The Fly reports. Several other research analysts also recently weighed in on MRNS. SVB Leerink reduced their target price on Marinus Pharmaceuticals from $27.00 to $23.00 and set an outperform rating […] ....